3.4.22.38: cathepsin K
This is an abbreviated version!
For detailed information about cathepsin K, go to the full flat file.
Word Map on EC 3.4.22.38
-
3.4.22.38
-
resorption
-
osteoporosis
-
osteoclastogenesis
-
rankl
-
tartrate-resistant
-
osteoblast
-
collagen
-
nfatc1
-
rankl-induced
-
multinucleated
-
mmp-9
-
c-fos
-
fracture
-
trabecular
-
pi
-
calcitonin
-
osteocalcin
-
osteoprotegerin
-
osteolytic
-
resorb
-
m-csf
-
collagenolytic
-
bisphosphonates
-
osteoclast-mediated
-
trap-positive
-
osteoclast-specific
-
odanacatib
-
oscar
-
antiresorptive
-
tracp
-
lacuna
-
ovariectomy-induced
-
rankl-mediated
-
dc-stamp
-
bone-resorbing
-
sclerostin
-
osteoclast-related
-
telopeptide
-
osteoclast-like
-
osteoclastogenic
-
denosumab
-
preosteoclasts
-
teriparatide
-
pharmacology
-
anti-osteoclastogenic
-
osteosclerosis
-
anti-osteoporotic
-
atp6v0d2
-
medicine
-
ranelate
-
drug development
-
deoxypyridinoline
-
rankl-stimulated
-
diagnostics
- 3.4.22.38
- resorption
- osteoporosis
-
osteoclastogenesis
- rankl
-
tartrate-resistant
- osteoblast
- collagen
- nfatc1
-
rankl-induced
-
multinucleated
- mmp-9
- c-fos
-
fracture
-
trabecular
- pi
- calcitonin
- osteocalcin
- osteoprotegerin
-
osteolytic
-
resorb
- m-csf
-
collagenolytic
- bisphosphonates
-
osteoclast-mediated
-
trap-positive
-
osteoclast-specific
- odanacatib
- oscar
-
antiresorptive
- tracp
- lacuna
-
ovariectomy-induced
-
rankl-mediated
-
dc-stamp
-
bone-resorbing
-
sclerostin
-
osteoclast-related
-
telopeptide
-
osteoclast-like
-
osteoclastogenic
-
denosumab
-
preosteoclasts
-
teriparatide
- pharmacology
-
anti-osteoclastogenic
- osteosclerosis
-
anti-osteoporotic
- atp6v0d2
- medicine
-
ranelate
- drug development
-
deoxypyridinoline
-
rankl-stimulated
- diagnostics
Reaction
Broad proteolytic activity. With small-molecule substrates and inhibitors, the major determinant of specificity is P2, which is preferably Leu, Met > Phe, and not Arg =
Synonyms
Cat K, Cat-K, cath K, cathepsin K, cathepsin O, Cathepsin O2, cathepsin-K, catK, Ctk, CTSK, Human osteoclast cathepsin K, More, OC-2 protein, rhCK
ECTree
Advanced search results
Application
Application on EC 3.4.22.38 - cathepsin K
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
diagnostics
-
to assess better the biology of CatK activity in vivo, a novel near-infrared fluorescence (NIRF) probe for imaging of CatK is developed
drug development
medicine
pharmacology
-
Cat K inhibitors might be useful for the treatment of osteoporosis
drug development
Cat S is an attractive therapeutic target and selective Cat S inhibitors may also modulate a number of other diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, asthma, atherosclerosis and neuropathic pain
drug development
-
cathepsin K inhibitors are regarded as a potential therapy for the treatment of bone loss, such as osteoporosis
drug development
-
cathepsin K is seen as an attractive target for intervention in the treatment of both osteoporosis and osteoarthritis
drug development
-
development of cathepsin K inhibitors as an approach for bone diseases with enhanced bone resorption
drug development
-
lysosomal cysteine protease is an interesting target molecule with therapeutic potential to attenuate bleomycin-induced pulmonary fibrosis in mice
drug development
-
lysosomal cysteine protease is an interesting target molecule with therapeutic potential to attenuate bleomycin-induced pulmonary fibrosis in mice
-
-
cathepsin K immunodetection may be a valuable adjunct in the correct classification of pulmonary adenocarcinomas, especially in small sclerosing bronchioloalveolar carcinomas, especially in small sclerosing bronchioloalveolar carcinomas and mixed adenocarcinoma subtypes with minimal infiltrative growth
medicine
-
cathepsin K is an attractive target for the development of therapies to treat osteoporosis
medicine
-
the serum level of cathepsin K could serve as a marker for fracture preduction and bone mineral density. The correlation between cathepsin K concentration in subjects without fractures and in those with multiple nontraumatic fractures are statistically significant. The cathepsin K levels of controls and patients with osteoporosis are significantly different
medicine
-
cathepsin K is linked to the pathogenesis of osteoporosis, arthritis, cardiovascular and respiratory diseases
medicine
-
cathepsin K is shown to play an essential role in rheumatoid arthritis, osteoarthritis, atherosclerosis, lung inflammation, amyloidosis, gaucher disease and obesity
medicine
-
catK plays an important role in melanoma invasion and metastasis by mediating intracellular degradation of matrix proteins after phagocytosis. Clinical use of catK inhibitors may be promising for the treatment of melanoma
medicine
-
it is shown that cathepsin K acts as a potent kinin-degrading enzyme in bloodstream. Contrary to cathepsin L, cathepsin K attenuates kallikrein-induced decrease of rat blood pressure, and reduces the hypotensive effect of bradykinin in a dose-dependant manner
medicine
-
it is suggested that cathepsin K plays an important role in the homeostasis of the dermal extracellular matrix and the dynamic equilibrium between matrix synthesis and proteolytic degradation, by counteracting deposition of matrix proteins during scar formation with its matrix-degrading activity
medicine
-
one genetic disorder is traced to cathepsin K: peridontopathia. Osteoblasts from these patients accumulate undigested collagen fibrils. Nonsense, missense and stop codon mutations have been shown in patients
medicine
-
the results suggest that cathepsin K plays an important role in the immune system and serves as a valid therapeutic target in autoimmune diseases
medicine
-
the results suggest that cathepsin K plays an important role in the immune system and serves as a valid therapeutic target in autoimmune diseases
medicine
-
inhibition of CTSK activity may decrease the risk of breast tumor progression
medicine
-
introduction of the enzyme, influencing the bone resorption, into bones might be helpful to stimulate and/or induce bone formation mechanisms, overview
medicine
-
because excessive bone remodeling is a key element in the pathogenesis of postmenopausal osteoporosis and other skeletal disorders, cathepsin K is a potential target for therapeutic intervention
medicine
-
cathepsin K is a marker of osteoclastic activity in periodontal disease
medicine
-
cathepsin K is a target for the pharmacological treatment of osteoporosis
medicine
-
cathepsin K is a target for the pharmacological treatment of osteoporosis
medicine
-
cathepsin K is a target for the pharmacological treatment of osteoporosis
medicine
-
cathepsin K is associated with skeletal and cardiovascular disorders, cathepsin K is a pharmaceutical industry target for treatment of osteoporosis
medicine
-
CTSK inhibitors are a potential novel therapeutic option to decrease squamous cell carcinoma progression
medicine
-
determination of cathepsin K and Cystatin C concentrations has no clinical significance in the prognosis of the survival time in lung cancer
medicine
-
serum cathepsin K is a marker of bone metabolism in postmenopausal women treated with alendronate
medicine
-
treatment with the potent cathepsin K inhibitor relacatib preserves cortical and trabecular bone mass in ovariectomized monkeys
medicine
-
cathepsin K inhibitors may aid in the management of canine osteosarcoma-related malignant osteolysis
medicine
human cathepsinK is a major drug target for the treatment of osteoporosis
medicine
activation of cathepsin K may be a promising strategy to prevent homing of therapy-resistant glioma stem-like cells (GSLCs) in niches and thus render these cells sensitive to chemotherapy and radiation
medicine
selective inhibition of cathepsin K has a therapeutic potential for diseases associated with bone loss and osseous inflammation, such as osteoarthritis, periodontitis, and osteoporosis. Cathepsin K inhibition may have anabolic effects on bone and cartilage regeneration that may be explained as a feedback response to cathepsin K depletion. The use of cathepsin K inhibition to reduce inflammation and associated bone resorption in equine osseous disorders may offer advantages to other therapeutics
pharmacology
-
CTSK is a possible therapeutic target in the treatment of obesity